Creative Biolabs is a global leader in tumor ferroptosis research, focusing on target screening, ferroptosis index analysis, and ferroptosis-mediated tumor therapy discovery, as well as commercial testing solutions. Together with our customers, we support the development of innovative ferroptosis drugs that change lives.
Introduction to Targeted Ferroptosis Cancer Therapy
The concept of ferroptosis, proposed in 2012, refers to a novel form of programmed cell death induced by the excessive accumulation of lipid peroxides within cells. Currently, the mechanism of ferroptosis mainly focuses on redox homeostasis disorder and iron homeostasis disorder. Targeted ferroptosis therapy has the potential to overcome drug resistance and other challenges in traditional cancer treatment. Ferroptosis can be induced in vivo through various methods, making it a promising approach for cancer treatment. For instance, GPX4 plays a central role in regulating ferroptosis, and inhibiting the GPX4-mediated anti-lipid oxidation pathway can induce ferroptosis. Targeted ferroptosis therapy holds great promise for optimizing comprehensive cancer treatment. As a result, Creative Biolabs elucidates the mechanism of ferroptosis and its role in tumor prevention and treatment while offering solutions for different types of cancer through targeted ferroptosis therapy. In the past decade, we have studied the molecular mechanism and metabolic basis of ferroptosis in depth, and are committed to developing new therapies to induce ferroptosis in tumor therapy.
Fig.1 The Role of Ferroptosis in Cancer Progression.1
Creative Biolabs targets critical regulatory molecules in the ferroptosis metabolic pathway, such as GPX4 and System Xc-. Hundreds of inducers and inhibitors have been developed to modulate these pivotal targets. Our current range of inducers is primarily composed of small molecules and drugs that target pathways associated with iron metabolism, lipid metabolism, the GSH/GPX4 axis, and FSP1/CoQ. The inhibitors consist mainly of small molecules that lower iron levels, decrease lipid peroxidation, and regulate the GSH/GPX4 axis. Moreover, we have identified proteins with inhibitory effects such as prominin2 which are also involved in iron metabolism and can be utilized for developing related inhibitors.
The CBL™ ferroptosis signaling pathway platform verifies and stores antibodies to more than 300 core target proteins and protein modification sites of ferroptosis signaling pathways, which can provide bioinformatics analysis and interpretation of proteomic big data related to these signaling pathways. Additionally, we offer advanced CRISPR-based screening for novel ferroptosis targets and standardized data processing to expedite the publication of your research findings.
With over a decade of experience in the field of ferroptosis, Creative Biolabs possesses a mature and stable platform for detecting the ferroptosis index, including routine assessments of iron metabolism, lipid peroxidation, reactive oxygen species, and glutathione metabolism. Furthermore, we are capable of assessing the expression levels of key proteins associated with ferroptosis such as PTGS2, NOX1, FTH1, COX2, GPX4, and ACSL4.
In recent years, inducing ferroptosis of tumor cells may become a feasible research direction for cancer therapy. Therefore, the compounds that induce ferroptosis and the mechanisms that cause ferroptosis of tumor cells have become the hotspot of anti-tumor drug development in our labs. We have been continuously revealing the novel metabolic mechanism of tumor cells' resistance to ferroptosis. While promoting the ferroptosis of tumor cells to mediate anti-tumor immunity, we are also studying the inhibition of ferroptosis-mediated immune escape of neighboring tumor cells, hoping to bring new ideas for tumor immunotherapy.
The development of small molecule drugs targeting ferroptosis regulatory networks has shown promising application prospects. Nowadays, our research team is developing new drugs that target ferroptosis to treat tumors. Up to now, we have been focusing on the GSH/GPX4 ferroptosis signaling pathways, and trying to discover small molecule and nanomaterial drugs to treat tumors related to digestive system tumors.
-
Leading global research and laboratory testing
-
Innovative science and insightful data/AI to inform decisions and guide your projects
-
Our passionate team is eager to advance your project goals and find solutions that save lives
Creative Biolabs provides one-stop testing, inspection, certification, metrology, and technical services related to ferroptosis to customers around the world, and is committed to driving oncology therapy innovation. In addition, for different ferroptosis signaling pathways, we have developed an LC-MS/MS-based absolute quantification system for the analysis of ferroptosis-related molecules. If you have any special needs in our ferroptosis services or are interested in learning more about our company, please feel free to contact us for more details.
Reference
-
Zhang, Rongyu, et al. "Ferroptosis in cancer progression." Cells 12.14 (2023): 1820.
For Research Use Only | Not For Clinical Use
Download our brochure